{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:39Z","timestamp":1793386479876,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40261-017-0528-x","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T12:08:30Z","timestamp":1492776510000},"page":"737-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review"],"prefix":"10.1007","volume":"37","author":[{"given":"Marina Dyskant","family":"Mochcovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Christophe","family":"da Rocha Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Ferreira","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Egidio","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"528_CR1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental health disorders 5th edition (DSM\u20135)","author":"American Psychiatric association","year":"2013","unstructured":"American Psychiatric association. Diagnostic and statistical manual of mental health disorders 5th edition (DSM\u20135). Washington: American Psychiatric Press; 2013."},{"key":"528_CR2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1176\/appi.ajp.162.6.1179","volume":"162","author":"SE Bruce","year":"2005","unstructured":"Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162:1179\u201387.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"528_CR3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1461145710001434","volume":"14","author":"DS Baldwin","year":"2011","unstructured":"Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14(5):697\u2013710.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 1","key":"528_CR4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive\u2013compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"528_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"B Bandelow","year":"2012","unstructured":"Bandelow B, Sher L, Bunevicius R, et al. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive\u2013compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77\u201384.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"4","key":"528_CR6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"C Allgulander","year":"2008","unstructured":"Allgulander C, Ayuso-Gutierrez J, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive\u2013compulsive and post-traumatic stress disorders\u2014first revision. World J Biol Psychiatry. 2008;9(4):248\u2013312.","journal-title":"World J Biol Psychiatry."},{"key":"528_CR7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/NDT.S36453","volume":"9","author":"DS Baldwin","year":"2013","unstructured":"Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883\u201392.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"528_CR8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/JCP.0b013e318224864d","volume":"31","author":"A Khan","year":"2011","unstructured":"Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release\u00a0quetiapine\u00a0fumarate (quetiapine\u00a0XR) monotherapy in patients with\u00a0generalized\u00a0anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418\u201328.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"528_CR9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.janxdis.2008.03.002","volume":"22","author":"MA Katzman","year":"2008","unstructured":"Katzman MA, Vermani M, Jacobs L, et al. Quetiapine\u00a0as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22(8):1480\u20136.","journal-title":"J Anxiety Disord"},{"issue":"4","key":"528_CR10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/YIC.0b013e3283457d73","volume":"26","author":"AC Altamura","year":"2011","unstructured":"Altamura AC, Serati M, Buoli M, Dell\u2019Osso B. Augmentative quetiapine in partial\/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011;26(4):201\u20135.","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"528_CR11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2147\/NDT.S67470","volume":"5","author":"MN Levitan","year":"2015","unstructured":"Levitan MN, Papelbaum M, Nardi AE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2015;5(11):1149\u201355.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"528_CR12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/17425255.2014.907794","volume":"10","author":"M Buoli","year":"2014","unstructured":"Buoli M, Mauri MC, Altamura AC. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. Expert Opin Drug Metab Toxicol. 2014;10(6):885\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"528_CR13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/14737175.2016.1173545","volume":"16","author":"L Orsolini","year":"2016","unstructured":"Orsolini L, Tomasetti C, Valchera A, et al. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother. 2016;16(5):483\u201395.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"528_CR14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/14656566.2013.759559","volume":"14","author":"M Buoli","year":"2013","unstructured":"Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother. 2013;14(2):175\u201384.","journal-title":"Expert Opin Pharmacother"},{"issue":"23","key":"528_CR15","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","volume":"283","author":"AJ Gelenberg","year":"2000","unstructured":"Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283(23):3082\u20138.","journal-title":"JAMA"},{"issue":"11","key":"528_CR16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.v66n1115","volume":"66","author":"JR Davidson","year":"2005","unstructured":"Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2005;66(11):1441\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"528_CR17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S1461145713001557","volume":"17","author":"S Kasper","year":"2014","unstructured":"Kasper S, Iglesias-Garc\u00eda C, Schweizer E, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014;17(5):685\u20139.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"528_CR18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eurpsy.2004.01.001","volume":"19","author":"F Rouillon","year":"2004","unstructured":"Rouillon F. Long term therapy of generalized anxiety disorder. Eur Psychiatry. 2004;19(2):96\u2013101.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"528_CR19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1461145705005973","volume":"9","author":"C Allgulander","year":"2006","unstructured":"Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9(5):495\u2013505.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"528_CR20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4088\/JCP.v64n0305","volume":"64","author":"F Stocchi","year":"2003","unstructured":"Stocchi F, Nordera G, Jokinen RH, et al. Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64(3):250\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"528_CR21","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/archgenpsychiatry.2010.170","volume":"67","author":"K Rickels","year":"2010","unstructured":"Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ. Time to relapse after 6 and 12\u00a0months\u2019 treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010;67(12):1274\u201381.","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"528_CR22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.euroneuro.2008.05.002","volume":"18","author":"JR Davidson","year":"2008","unstructured":"Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(9):673\u201381.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"528_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/YIC.0b013e3282f0f0d7","volume":"23","author":"D Feltner","year":"2008","unstructured":"Feltner D, Wittchen H-U, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18\u201328.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"528_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/YIC.0b013e32833e34d9","volume":"26","author":"MA Katzman","year":"2011","unstructured":"Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11\u201324.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"528_CR25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4088\/JCP.11m07493","volume":"73","author":"DJ Stein","year":"2012","unstructured":"Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(7):1002\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"528_CR26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0b013e3283530ad7","volume":"27","author":"DS Baldwin","year":"2012","unstructured":"Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197\u2013207.","journal-title":"Int Clin Psychopharmacol"},{"key":"528_CR27","unstructured":"Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from \n                        http:\/\/www.handbook.cochrane.org\n                        \n                    ."},{"key":"528_CR28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1176\/appi.ajp.162.6.1179","volume":"162","author":"SF Bruce","year":"2005","unstructured":"Bruce SF, Yonkers KA, Otto MW, et al. Influence of psychiatry comorbidity on recovery and recurrence of generalized anxiety disorder, social phobia and panic disorder: a 12-year prospective study. Am J psychiatry. 2005;162:1179\u201387.","journal-title":"Am J psychiatry"},{"issue":"2","key":"528_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/01.nmd.0000198140.02154.32","volume":"194","author":"BF Rodriguez","year":"2006","unstructured":"Rodriguez BF, Weisberg RB, Pagano ME, et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis. 2006;194(2):91\u20137.","journal-title":"J Nerv Ment Dis"},{"key":"528_CR30","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","volume":"67","author":"B Bandelow","year":"2006","unstructured":"Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67:1428\u201334.","journal-title":"J Clin Psychiatry"},{"key":"528_CR31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/NDT.S36453","volume":"9","author":"DS Baldwin","year":"2013","unstructured":"Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883\u201392.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"528_CR32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17425255.2017.1281247","volume":"13","author":"M Buoli","year":"2017","unstructured":"Buoli M, Caldiroli A, Serati M. Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. Expert Opin Drug Metab Toxicol. 2017;13(3):351\u20139.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0528-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0528-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0528-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T06:08:47Z","timestamp":1499926127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0528-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0528-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}